🚀 VC round data is live in beta, check it out!
Larimar Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Larimar Therapeutics and similar public comparables like Zura Bio, Fulcrum Therapeutics, Entrada Therapeutics, Opthea and more.
Larimar Therapeutics Overview
About Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Founded
2005
HQ
Employees
65
Website
Sectors
Financials (LTM)
EV
$398M
Larimar Therapeutics Financials
Larimar Therapeutics reported last 12-month revenue of — and negative EBITDA of ($171M).
In the same LTM period, Larimar Therapeutics generated — in gross profit, ($171M) in EBITDA losses, and had net loss of ($177M).
Revenue (LTM)
Larimar Therapeutics P&L
In the most recent fiscal year, Larimar Therapeutics reported revenue of — and EBITDA of ($169M).
Larimar Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($171M) | XXX | ($169M) | XXX | XXX | XXX |
| Net Profit | ($177M) | XXX | ($166M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Larimar Therapeutics Stock Performance
Larimar Therapeutics has current market cap of $530M, and enterprise value of $398M.
Market Cap Evolution
Larimar Therapeutics' stock price is $5.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $398M | $530M | 0.3% | XXX | XXX | XXX | $-1.59 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLarimar Therapeutics Valuation Multiples
Larimar Therapeutics trades at (2.3x) EV/EBITDA.
EV / Revenue (LTM)
Larimar Therapeutics Financial Valuation Multiples
As of April 11, 2026, Larimar Therapeutics has market cap of $530M and EV of $398M.
Equity research analysts estimate Larimar Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Larimar Therapeutics has a P/E ratio of (3.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $530M | XXX | $530M | XXX | XXX | XXX |
| EV (current) | $398M | XXX | $398M | XXX | XXX | XXX |
| EV/EBITDA | (2.3x) | XXX | (2.4x) | XXX | XXX | XXX |
| EV/EBIT | (2.2x) | XXX | (2.3x) | XXX | XXX | XXX |
| P/E | (3.0x) | XXX | (3.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Larimar Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Larimar Therapeutics Margins & Growth Rates
Larimar Therapeutics' revenue in the last fiscal year grew by —.
Larimar Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.7M for the same period.
Larimar Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 3% | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.7M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Larimar Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zura Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Fulcrum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Entrada Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Opthea | XXX | XXX | XXX | XXX | XXX | XXX |
| Knight Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Larimar Therapeutics M&A Activity
Larimar Therapeutics acquired XXX companies to date.
Last acquisition by Larimar Therapeutics was on XXXXXXXX, XXXXX. Larimar Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Larimar Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLarimar Therapeutics Investment Activity
Larimar Therapeutics invested in XXX companies to date.
Larimar Therapeutics made its latest investment on XXXXXXXX, XXXXX. Larimar Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Larimar Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Larimar Therapeutics
| When was Larimar Therapeutics founded? | Larimar Therapeutics was founded in 2005. |
| Where is Larimar Therapeutics headquartered? | Larimar Therapeutics is headquartered in United States. |
| How many employees does Larimar Therapeutics have? | As of today, Larimar Therapeutics has over 65 employees. |
| Who is the CEO of Larimar Therapeutics? | Larimar Therapeutics' CEO is Carole Ben-Maimon. |
| Is Larimar Therapeutics publicly listed? | Yes, Larimar Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Larimar Therapeutics? | Larimar Therapeutics trades under LRMR ticker. |
| When did Larimar Therapeutics go public? | Larimar Therapeutics went public in 2020. |
| Who are competitors of Larimar Therapeutics? | Larimar Therapeutics main competitors are Zura Bio, Fulcrum Therapeutics, Entrada Therapeutics, Opthea. |
| What is the current market cap of Larimar Therapeutics? | Larimar Therapeutics' current market cap is $530M. |
| Is Larimar Therapeutics profitable? | No, Larimar Therapeutics is not profitable. |
| What is the current EBITDA of Larimar Therapeutics? | Larimar Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Larimar Therapeutics? | Current EBITDA multiple of Larimar Therapeutics is (2.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.